IVA
Inventiva SaNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.11B
P/E Ratio
—
EPS
$-2.19
Beta
0.95
52W High
$7.98
52W Low
$2.85
50-Day MA
$6.20
200-Day MA
$4.95
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Inventiva Sa
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidosis (MPS) and other diseases. The company is headquartered in Daix, France.
Fundamentals
| Revenue (TTM) | $7.93M |
| Gross Profit (TTM) | $7.93M |
| EBITDA | $-138.86M |
| Operating Margin | -3686.00% |
| Return on Equity | -1643.00% |
| Return on Assets | -56.80% |
| Revenue/Share (TTM) | $0.04 |
| Book Value | $-0.07 |
| Price-to-Book | 4.58 |
| Price-to-Sales (TTM) | 139.90 |
| EV/Revenue | 198.66 |
| EV/EBITDA | -1.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -79.60% |
| Shares Outstanding | $207.65M |
| Float | $146.27M |
| % Insiders | 0.00% |
| % Institutions | 35.46% |
Analyst Ratings
Consensus ($15.13 target)
2
Strong Buy11
BuyData last updated: 4/8/2026